Gout & crystal arthritis

Tophus measurement as an outcome measure in gout: an updated systematic literature review

Semin Arthritis RheumPublished Systematic literature review

Authors' conclusion

There is evidence to support the feasibility, truth and discrimination of Vernier callipers. US, DECT and the TIQ-20 fulfil many aspects of the Filter but have not yet demonstrated a difference between arms of a RCT.

Study context

Population
Publications on methods of tophus measurement in gout (2010 to 2024, plus pre-2010 publications from a 2011 review)10 methods identified
Comparison
Vernier callipers vs ultrasound (US) vs dual-energy computed tomography (DECT) vs Tophus Impact Questionnaire (TIQ-20)
Outcome
Feasibility, truth and discrimination of tophus measurement methods (OMERACT Filter 2.2)
Methodological detailsupdated review, evaluation against OMERACT Filter 2.2
  • Updated review
  • Evaluation against OMERACT Filter 2.2

Main finding

As reported in the abstract

Performance of tophus measurement methods against OMERACT Filter 2.2
  • Ten methods identified: tophus count, tape measurement, Vernier callipers, digital photography, US, computed tomography (CT), DECT, magnetic resonance imaging (MRI), plain radiography and TIQ-20
  • Vernier callipers correlated well with other physical measurement techniques, had good to excellent reliability, and showed responsiveness to treatment and discrimination
  • US and DECT had excellent reliability and responsiveness to treatment, but no difference in tophus size yet shown in an randomized controlled trial (RCT); higher cost and training requirements
  • TIQ-20 had high feasibility and responsiveness; its discrimination needs further research

Original publication

Tophus measurement as an outcome measure in gout: an updated systematic literature review. Semin Arthritis Rheum. Published 15 May 2026. doi:10.1016/j.semarthrit.2026.153000

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.